News & Research
Why Researchers Are Testing Semaglutide for Alcohol Use Disorder
A planned trial of up to 1,200 people puts semaglutide back in the alcohol conversation. Here is what human studies have found, what remains uncertain and why help need not wait.
A headline about Ozempic and drinking can raise a very personal question: could medication make alcohol feel less compelling? For someone tired of negotiating with the urge to drink, that possibility matters.
Researchers are investigating it. Several randomized trials have reported encouraging results for semaglutide, the medicine used in Ozempic and Wegovy. A larger study announced this month will ask what it can add to existing addiction care. But semaglutide is not FDA-approved to treat alcohol use disorder, and the results so far need a closer look than a headline allows.
What is new this month
On October 13, the Center for Addiction Science, Policy and Research, or CASPR, and Pennsylvania’s Allegheny County Department of Human Services announced plans for a $13.3 million randomized trial. The study is expected to begin in early 2027 and enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both.
According to the announcement, half the participants will be assigned weekly semaglutide for 52 weeks alongside existing care. Recruitment will focus on people at elevated risk of criminal-justice involvement. Researchers also plan to examine outcomes such as housing, employment and health care use.
Those details matter. This is a planned study, not a completed trial with results. Its specific recruitment focus also means the eventual findings may not apply to everyone considering a change in drinking.
Why a diabetes and weight-management medicine is being studied
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. GLP-1 pathways help regulate appetite and are involved in reward. That has prompted researchers to ask whether these medicines could also affect alcohol craving and consumption.
A plausible explanation is only a starting point. To find out whether a medicine helps, researchers need to compare it with a control, measure drinking carefully and watch for harms. Personal reports of losing interest in alcohol cannot answer all of those questions.
The useful question is what the medicine adds to care, for whom, and at what cost in side effects.
What the human trials have found
A 2026 trial published in The Lancet enrolled 108 adults with moderate to severe alcohol use disorder who also had obesity. Participants received weekly semaglutide or placebo for 26 weeks, with cognitive behavioral therapy offered to both groups. Eighty-eight completed the trial.
Heavy-drinking days decreased in both groups. The semaglutide group had a larger decline, with an adjusted difference of 13.7 percentage points in the change in the proportion of heavy-drinking days. That is a group comparison of drinking frequency, not the percentage of people cured or a promise about an individual’s results.
The population is important: this study cannot tell us how well the treatment would work for everyone with alcohol use disorder, including people without obesity. Gastrointestinal side effects were more common with semaglutide.
Another randomized trial, published online in the American Journal of Psychiatry in July 2026, studied oral semaglutide in 50 treatment-seeking adults with moderate to severe alcohol use disorder and a body mass index of at least 25. Over eight weeks, it did not find a significant advantage on its primary outcome, laboratory-measured alcohol craving, or on average drinks per day. It did find fewer heavy-drinking days during the final four weeks, a secondary outcome, and fewer drinks on drinking days compared with placebo.
These results separate two questions: whether someone drinks heavily less often and whether craving changes in a laboratory test. The oral trial gave different answers. Larger studies will need to establish how reliable those differences are.
What is still unsettled
- Who benefits most, including people with different health conditions and drinking patterns.
- How benefits and side effects compare with established alcohol-use-disorder treatments.
- How durable any benefit is, including after treatment stops.
- How the medicine would fit into everyday care beyond a supervised trial.
The announced Pittsburgh-area study may help answer some of these questions by following a larger group for a full year alongside existing care.
What this means if you want help now
You do not have to wait for a new trial to ask about treatment. NIAAA lists three FDA-approved medicines for alcohol use disorder: naltrexone, acamprosate and disulfiram. Behavioral treatment and mutual-support options are also available. A clinician can help you consider your goals, medical history and the care that fits.
If you are already prescribed a GLP-1 medicine and notice a change in drinking, tell your prescriber. Do not start, stop, increase or swap medication on the strength of an alcohol headline. Semaglutide has important warnings and is unsuitable for some people; trial participation involves screening and clinical oversight that a social-media anecdote does not provide.
For an appointment, you might write down a few concrete questions: “What treatments are available for my drinking?” “Would medication be appropriate for me?” “How would we judge whether it is helping?” You can discuss cutting back, stopping or uncertainty about either without arriving with your own diagnosis.
If you have been drinking heavily over a prolonged period, seek medical advice before abruptly stopping. Alcohol withdrawal can be life-threatening. Semaglutide research does not provide a way to manage withdrawal on your own.
You can be interested in what comes next without postponing help that is available now.
A story worth following carefully
The change worth watching is the move from personal anecdotes toward controlled studies, with results that can be questioned and compared. Some findings are promising. Others are mixed, and the newest large trial is still a plan.
For now, the most useful thing to take from this story may be a question for a clinician, rather than a medication name to shop for: what could make changing my drinking more manageable?
Continue reading
For a closer look at how people experience alcohol cravings, read our research explainer.
Frequently Asked Questions
Is semaglutide approved for alcohol use disorder?
No. As checked on October 26, 2026, semaglutide has no FDA-approved indication for alcohol use disorder. Research use should not be confused with an approved treatment indication.
Do these studies show that Ozempic cures addiction?
No. Trials have measured changes in drinking and related outcomes over specific periods. Results from semaglutide studies do not establish a cure, guarantee individual benefit or prove that every GLP-1 medicine has the same effects.
Has the new 1,200-person trial reported results?
No. The October 13 announcement described a planned trial expected to launch in early 2027, with enrollment of up to 1,200 people. Its schedule and enrollment plans should be checked again as the study develops.
Should I wait for this research before seeking help?
No. Established treatment options are available now. A qualified health care professional can discuss medication, behavioral care and other support, including whether stopping suddenly could be unsafe for you.
